What is OncoQuest?
OncoQuest, a subsidiary of Quest PharmaTech Inc. (TSXV: QPT), is dedicated to the development and commercialization of novel immunotherapies for cancer treatment. The company's proprietary technology platform features a robust portfolio of tumor antigen-specific monoclonal immunoglobulins, including those targeting CA-125, MUC1, PSA, and Her2/neu. OncoQuest is actively investigating the synergistic potential of these antibodies when administered in combination with other immune-modulating drugs, aiming to amplify tumor-specific immunity and improve patient outcomes.
How much funding has OncoQuest raised?
OncoQuest has raised a total of $50M across 1 funding round:
Share Placement
$50M
Share Placement (2020): $50M with participation from Dual Industrial Co. Ltd.
Key Investors in OncoQuest
Dual Industrial Co. Ltd.
Dual Industrial Co. Ltd. is an entity participating in the recent funding round, with its specific investment focus not detailed.
What's next for OncoQuest?
The recent major strategic investment positions OncoQuest for accelerated growth and the advancement of its preclinical and clinical pipelines. With a focus on enhancing tumor-specific immunity, the company is poised to explore new therapeutic combinations and expand its market reach. This capital infusion is expected to fuel further research and development, potentially leading to groundbreaking treatments in the competitive landscape of cancer immunotherapy.
See full OncoQuest company page
